Pharma plant explosion in India kills 3 workers

An explosion at a biotech plant near New Delhi in India has left workers dead. (Pixabay)

For the second time in eight weeks, there have been deaths tied to an explosion at a pharmaceutical manufacturing facility, this time in India.

Three workers were killed instantly when the boiler they were working on at Pusilin Biotechnology Private exploded, the Xinhua News Agency reported. The plant is in Haryana, near New Delhi.

According to the Chinese Embassy in India, two of the engineers were Chinese and one was Indian, the news agency reported.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

It was in April that 10 workers died of smoke inhalation caused by an explosion and fire at a Chinese drug manufacturing plant. The explosion at the Qilu Tianhe Huishi Pharmaceutical Co. facility in eastern Shandong province was caused by sparks as workers welded a pipe under the plant.

RELATED: 10 killed in explosion at Chinese pharma plant

That explosion, in turn, followed one in March at a chemical plant in eastern Jiangsu province that killed 78 and injured hundreds. Those blasts again raised questions about the safety conditions at pharma plants in China.

In 2015, a massive fire and explosions in the Tianjin industrial port in China killed 160 people and left a massive area of destruction. GlaxoSmithKline had to stop production at a plant in the area following the blasts. No GSK workers were hurt by the nearby event, but the facility was damaged.

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.